Pricing Log in Create free account
Saturday 17 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.71 0.86 −1.42%
Market cap
$123.7B
P/E
13.2×
Fwd P/E
11.2×
Dividend yield
4.22%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Bristol Myers Squibb Company (BMY) trades at a price to free cash flow of 10.7×. Over the past ten years it has ranged from 5.7× (October 2025) to 382× (June 2016); the current reading is higher than 34% of that period. That is below the Drug Manufacturers General industry median of 16.5× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 8.5× 3.87%
FY2024 8.2× (4.70%)
FY2023 8.6× (33.02%)
FY2022 12.9× 41.71%
FY2021 9.1× (13.69%)
FY2020 10.5× (29.04%)
FY2019 14.8× 6.92%
FY2018 13.9× (41.92%)
FY2017 23.9× (55.66%)
FY2016 53.9× (39.60%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 10.3× (0.92%)
Mar 2026 10.4× 21.53%
Dec 2025 8.5× 42.34%
Sep 2025 6.0× (7.13%)
42 more quarters

Against its own ten years

Low 5.7× High 382×
Ten-year median 12.0×
Current reading's percentile 34

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.7×
BMY Bristol Myers Squibb Company 10.7×
GSK GSK PLC Sponsored ADR compare 13.0×
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. compare 16.5×
NVS Novartis AG compare 18.9×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 24.0×
AZN AstraZeneca PLC compare 40.9×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on BMY